BioCryst Pharmaceuticals (NASDAQ: BCRX) had a Thursday to forget, at least as far as its stock was concerned. The company's shares took an almost 4% tumble that day, due to first-quarter results that investors clearly considered inadequate.
For the quarter, BioCryst booked $49.9 million in revenue, which was more than double the slightly over $19 million in the same period of 2021. Nearly all of the latest top-line figure derived from the company's latest FDA-approved and commercialized product, hereditary angioedema (HAE) drug Orladeyo.
Image source: Getty Images.
For further details see:
Why BioCryst Stock Lost Nearly 4% of Its Value Today